Walleye Capital LLC Sells 6,655 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Walleye Capital LLC decreased its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 14.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,829 shares of the company’s stock after selling 6,655 shares during the quarter. Walleye Capital LLC owned approximately 0.06% of Health Catalyst worth $316,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HCAT. First Light Asset Management LLC grew its position in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares during the last quarter. Impax Asset Management Group plc lifted its stake in shares of Health Catalyst by 16.4% in the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after acquiring an additional 360,201 shares during the period. Millennium Management LLC boosted its holdings in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after acquiring an additional 1,184,131 shares during the last quarter. Primecap Management Co. CA increased its position in Health Catalyst by 1.1% during the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after purchasing an additional 25,000 shares during the period. Finally, Daventry Group LP raised its holdings in Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after purchasing an additional 84,178 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Evercore ISI upped their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Citigroup increased their price target on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Stephens raised their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Finally, Royal Bank of Canada boosted their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $8.34 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a fifty day simple moving average of $8.13 and a two-hundred day simple moving average of $7.39. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41. The firm has a market capitalization of $507.47 million, a PE ratio of -6.18 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.22) earnings per share. Analysts forecast that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Insider Activity at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total transaction of $67,050.00. Following the transaction, the insider now directly owns 236,950 shares of the company’s stock, valued at $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at $1,036,024.32. The trade was a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,566 shares of company stock valued at $169,130 over the last 90 days. Insiders own 2.50% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.